Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older.

George, Sydney; Carrico, Justin; Hicks, Katherine A; Loukov, Dessi; Ng, Cheryl; Regan, Jessica; Giannelos, Nikolaos

Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older.

George, Sydney; Carrico, Justin; Hicks, Katherine A; Loukov, Dessi; Ng, Cheryl; Regan, Jessica; Giannelos, Nikolaos.

Afiliación

George S; GSK, Mississauga, ON, Canada. sydney.a.george@gsk.com.
Carrico J; RTI Health Solutions, Research Triangle Park, NC, USA.
Hicks KA; RTI Health Solutions, Research Triangle Park, NC, USA.
Loukov D; GSK, Mississauga, ON, Canada.
Ng C; GSK, Singapore, Singapore.
Regan J; GSK, Mississauga, ON, Canada.
Giannelos N; GSK, Wavre, Belgium.

Pharmacoecon Open ; 8(5): 785, 2024 Sep.

Article en En | MEDLINE | ID: mdl-39017906

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmacoecon Open Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google